IGM Biosciences Inc. (IGMS) Misses Q2 EPS by 75c; offers guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Morgan Stanley Reiterates Overweight Rating on IGM Biosciences (IGMS)
August 14, 2024 12:04 PM EDTMorgan Stanley analyst Michael Ulz reiterated an Overweight rating and $12.00 price target on IGM Biosciences (NASDAQ: IGMS)
The analyst comments "Reported 2Q24 highlighted progress across the early stage pipeline as Ph1b dose escalation continues for imvotamab in RA and... More
